查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1627874

嗜伊紅性食道炎治療市場：預測（2025-2030）

Eosinophilic Esophagitis Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計嗜伊紅性食道炎治療市場在預測期內將以8.15%的複合年成長率成長，從2025年的504,625,000美元增加到2030年的745,096,000美元。

嗜伊紅性食道炎(EoE) 是一種過敏性發炎性疾病，涉及嗜酸性粒細胞（一種白血球）。主要症狀包括胃灼熱、胸痛和吞嚥困難。目前還沒有治療 EOE 的主要藥物，有幾種食物可以引起 EOE，包括貝類、魚露和蠔油。

全球氣喘和過敏患者數量的增加預計將推動全球嗜伊紅性食道炎治療市場的發展。患有EoE的患者主要患有過敏性鼻炎、食物過敏、氣喘等其他疾病。美國氣喘和過敏基金會在報告中指出，約76%的EoE患者有食物過敏，70%有過敏性鼻炎，51%有氣喘。此外，41% 的人患有異位性皮膚炎，16% 的人患有大腸激躁症。

嗜伊紅性食道炎治療市場的地理前景：

  • 預計北美地區在預測期內複合年成長率最高。

這種疾病在美國的盛行率不斷上升，是未來幾年 EoE 治療需求增加的主要原因之一。例如，國家罕見疾病組織 (NORD) 在 2024 年 3 月發表了一篇關於嗜伊紅性食道炎的論文，指出如果以美國人口為標準，美國10 萬人中有 56.7 人患有嗜酸性粒總合嗜伊紅性食道炎。此外，過去 20 年來，美國成人和兒童的 EoE 病例幾乎加倍。因此，此類統計數據預計將在未來幾年推動嗜伊紅性食道炎治療市場的發展。

此外，EoE 治療的核准數量不斷增加預計也將對未來幾年的市場成長產生積極影響。例如，2024年1月，美國食品藥物管理局（FDA）核准Dupixent®（dupilumab）用於治療1歲以上兒童的EoE。此次核准延長了核准核准2022 年 5 月對適用於 12 歲及以上、體重 40 公斤的 EoE 的初步批准。 FDA 對 Dupixent 的這種擴大適應症進行了優先審查，表明該藥物能夠有效、安全地治療這種罕見疾病。因此，此類產品的推出是預測期內市場成長的主要動力之一。

此外，預計該國醫療保健支出的增加將在預測期內推動市場成長。例如，根據美國醫療保險和醫療補助服務中心（美國 Medical Services）的數據，2021年人均醫療保健支出為12,914美元，醫療保健支出總額為43億美元。到 2022 年，這一數字將增加至醫療保健總支出 45 億美元，人均醫療保健支出達 13,493 美元。因此，人均醫療保健支出的增加預計也將對預測期內嗜伊紅性食道炎治療市場的成長產生積極影響。

為什麼要購買這份報告？

  • 富有洞察力的分析：獲得涵蓋關鍵和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、行業和其他子區隔。
  • 競爭格局：了解世界主要企業採取的策略策略，並了解透過正確的策略滲透市場的潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中發現新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業有用且具有成本效益。

它有什麼用？

產業和市場考量、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2022年至2030年歷史資料與預測
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 各國收益成長和預測細分市場和區域分析
  • 公司概況（尤其是主要趨勢）

嗜伊紅性食道炎治療市場分為以下幾個部分：

依產品類型

  • 仿單標示外藥物
  • Budesonide口服懸浮液
  • FluticasoneODT
  • 美泊利單抗
  • 瑞利珠單抗
  • 貝那利珠單抗
  • 度匹魯單抗
  • Omalizumab

按分銷管道

  • 醫院藥房
  • 零售藥房
  • 網路藥房

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 其他
  • 中東/非洲
  • 沙烏地阿拉伯
  • UAE
  • 其他
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 印尼
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程
  • 資料檢驗

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章嗜伊紅性食道炎治療市場：產品平臺

嗜伊紅性食道炎治療市場：依產品類型

  • 介紹
  • 仿單標示外藥物
  • Budesonide口服懸浮液
  • FluticasoneODT
  • 美泊利單抗
  • 瑞利珠單抗
  • 貝那利珠單抗
  • 度匹魯單抗
  • Omalizumab

第7章嗜伊紅性食道炎治療市場：依通路分類

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章嗜伊紅性食道炎治療市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 印尼
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 新興企業和市場盈利
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Ellodi Pharmaceuticals
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Plc
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Pfizer
  • Landos Biopharma, Inc.
  • DBV Technologies
  • Calypso Biotech
  • Revolo Biotherapeutics
  • Allakos Inc.
  • Regeneron Pharmaceutical
簡介目錄
Product Code: KSI061612287

The eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.15% over the forecast period, increasing from US$504.625 million in 2025 to US$745.096 million by 2030.

Eosinophilic esophagitis (EoE) is a type of allergic inflammatory disease that involves a white blood cell type, eosinophils. Its major symptoms include heartburn, chest pain, and difficulty in swallowing. There are no major medicines that can cure EOE, and multiple foods like shellfish, fish sauce, and oyster sauce can cause it.

The global increase in asthma and allergy cases is estimated to push the global eosinophilic esophagitis disease treatment market forward. The patients suffering from EOE majorly have other conditions like allergic rhinitis, food allergies, or asthma. The Asthma and Allergy Foundation of America, in its report, stated that about 76% of EOE patients have food allergy as a comorbid condition, 70% have Allergic rhinitis, and 51% have asthma. The comorbid condition prevalence of atopic dermatitis and irritable bowel syndrome are 41% and 16%, respectively.

Eosinophilic Esophagitis Disease Treatment Market Geographical Outlook:

  • The North American region is expected to propel with the highest CAGR in the projected period.

The rising prevalence of this disease in the United States is one of the major reasons for the increased demand for EoE treatment in the coming years. For instance, the National Organization for Rare Disorders, Inc. (NORD) which published an article in March 2024, on Eosinophilic Esophagitis, stated that standardized to the U.S. population it has been estimated that 56.7 per 1,00,000 people in the US are suffering from eosinophilic esophagitis disease, which makes a total of 1,52,152 cases in total. Additionally, in the past two decades in the U.S., the cases of EoE have almost doubled in both adults and children. Hence, such stats are anticipated to fuel the eosinophilic esophagitis disease treatment market in the coming years.

The rising drug approval for the treatment of this disease of also expected to have a positive impact on the market growth in the coming years. For instance, in January 2024, the Food and Drug Administration (FDA) in the United States approved Dupixent(R) (dupilumab) for treating EoE for children aged 1 year or older. This approval extends the initial FDA approval for EOE in May 2022 for patients aged 12 years and older and weighing 40 kg. The FDA evaluated Dupixent for this expanded indication under priority review, and this drug proved to have efficiently and safely treated this rare condition. Hence, these product launches are one of the main reasons for market growth in the projected period.

Additionally, the rising healthcare expenditure in the country is anticipated to fuel the market growth in the forecasted period. For instance, according to the U.S. Centers for Medicare & Medicaid Services, and American Medical Services, the per capita healthcare expenditure in 2021 was US$12,914 or US$4.3 billion in total spend in healthcare. This number increased to US$4.5 billion in total healthcare spending, and per capita spending of US$13,493 in 2022. Hence, in the projected period, rising per capita healthcare spending is also expected to positively impact the eosinophilic esophagitis disease treatment market growth.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Eosinophilic Esophagitis Disease Treatment Market is analyzed into the following segments:

By Product Type

  • Off-Label Drugs
  • Budesonide Oral Suspension
  • Fluticasone ODT
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • Dupilunab
  • Omalizumab

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process
  • 2.3. Data Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY PRODUCT PIPELINE

6. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. Off-Label Drugs
  • 6.3. Budesonide Oral Suspension
  • 6.4. Fluticasone ODT
  • 6.5. Mepolizumab
  • 6.6. Reslizumab
  • 6.7. Benralizumab
  • 6.8. Dupilumab
  • 6.9. Omalizumab

7. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies
  • 7.4. Online Pharmacies

8. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Ellodi Pharmaceuticals
  • 10.2. AstraZeneca Plc
  • 10.3. Bristol-Myers Squibb Co
  • 10.4. GlaxoSmithKline Plc
  • 10.5. Sanofi
  • 10.6. Takeda Pharmaceutical Company Limited
  • 10.7. Pfizer
  • 10.8. Landos Biopharma, Inc.
  • 10.9. DBV Technologies
  • 10.10. Calypso Biotech
  • 10.11. Revolo Biotherapeutics
  • 10.12. Allakos Inc.
  • 10.13. Regeneron Pharmaceutical